How to take retatrutide injection safely is an important question for anyone enrolled in a clinical trial investigating this novel triple receptor agonist. Retatrutide targets GLP-1, GIP, and glucagon receptors simultaneously, making it a potentially significant advance in the management of obesity and type 2 diabetes. However, retatrutide has not yet received MHRA or EMA approval for routine clinical use in the UK. This guide covers injection technique, dosing schedules, site rotation, side effects, and storage — all of which must be followed alongside the specific instructions provided by your supervising clinical trial team.

What Is Retatrutide and How Does It Work?

Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, not yet approved by the MHRA or EMA for routine clinical use in the UK.

Retatrutide is an investigational injectable medication currently under clinical development for the management of obesity and type 2 diabetes. It belongs to a novel class of agents known as triple receptor agonists, targeting three key hormonal receptors simultaneously: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This triple-action mechanism distinguishes it from existing approved therapies such as semaglutide (a GLP-1 receptor agonist) or tirzepatide (a dual GIP/GLP-1 agonist).

By activating GLP-1 receptors, retatrutide helps stimulate insulin secretion in a glucose-dependent manner, reduces appetite, and slows gastric emptying — contributing to improved blood glucose control and reduced caloric intake. The GIP receptor component may further support insulin release. Glucagon receptor agonism is thought to increase energy expenditure and promote fat breakdown, though the precise clinical significance of each component in humans continues to be investigated in ongoing trials.

It is important to note that retatrutide has not yet received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA) for routine clinical use in the UK. No UK Summary of Product Characteristics (SmPC) or European Public Assessment Report (EPAR) currently exists for this medicine. Its use outside of formally approved clinical trials is not sanctioned. For the latest regulatory status, refer to the MHRA medicines search page and the EMA medicines search page.

Patients should not attempt to obtain or self-administer retatrutide outside of a formally supervised research or medical setting. Always consult a qualified healthcare professional before considering any new injectable therapy.

How to Inject Retatrutide Safely and Correctly

Retatrutide is given as a subcutaneous injection; hands must be washed, the solution inspected, and a new sterile needle used each time, following trial-specific training and protocol.

Retatrutide is administered as a subcutaneous injection — delivered into the fatty tissue just beneath the skin. Because no approved product licence or SmPC currently exists for retatrutide in the UK, the device-specific instructions below reflect general best practice for subcutaneous self-injection. All participants in clinical trials must follow the specific training, protocol, and instructions provided by their trial team, which take precedence over any generic guidance.

Before injecting, always follow these preparatory steps:

• Check the expiry date on the device and confirm you have the correct medicine, dose, and scheduled time.

• Wash your hands thoroughly with soap and water for at least 20 seconds.

• Inspect the solution — if it appears cloudy, discoloured, or contains visible particles, do not use it; contact your clinical team.

• Allow the medication to reach room temperature before use if it has been refrigerated, in accordance with your trial protocol instructions.

• Do not shake the device.

• Prime the device if instructed to do so by your trial protocol or device training.

When administering the injection, pinch a fold of skin gently at the chosen site, insert the needle at a 90-degree angle (or 45 degrees if you have very little subcutaneous fat), and press the plunger slowly and steadily. Hold the needle in place for several seconds after delivery to ensure the full dose is administered, then withdraw smoothly. Apply gentle pressure with a clean cotton swab — do not rub, as this may affect absorption. Always use a new, sterile needle for each injection and never share devices with another person.

For further guidance on subcutaneous injection technique, refer to the Forum for Injection Technique (FIT) UK Injection Technique Recommendations and NHS guidance on self-injection.

Recommended Doses and Injection Schedule

Clinical trials have used once-weekly subcutaneous doses ranging from approximately 1 mg to 12 mg, escalated gradually under medical supervision; all dosing must follow your trial protocol exactly.

In clinical trials investigating retatrutide, a dose-escalation approach has been used to minimise gastrointestinal side effects and improve tolerability. Participants typically begin on a low starting dose, which is gradually increased over a period of weeks or months under medical supervision. Published Phase 2 trial data (for example, Jastreboff et al., NEJM 2023) have explored doses ranging from approximately 1 mg up to 12 mg administered once weekly; however, these are investigational trial doses and do not constitute approved prescribing information.

The once-weekly subcutaneous injection schedule is consistent with other agents in the incretin-based therapy class, such as semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro). Injections should be administered on the same day each week, in accordance with your trial protocol.

Key points regarding dosing:

• If you miss a dose, follow the instructions in your trial protocol exactly. Do not take an extra dose to make up for a missed one. If you are unsure what to do, contact your clinical team before taking any action.

• Never adjust your dose without explicit guidance from your prescribing clinician or trial team.

• Dose escalation timelines are determined by your healthcare team based on tolerability and clinical response.

Because retatrutide is not yet approved for general prescribing in the UK, all dosing information must be treated as trial-protocol specific. Follow only the instructions provided directly by your supervising clinician or trial protocol. Refer to the relevant ClinicalTrials.gov or EudraCT entry for your study for further detail.

Where to Inject and How to Rotate Sites

Inject into the abdomen, front of the thighs, or upper outer arms, rotating sites at least 1–2 cm apart each week to prevent lipohypertrophy and maintain consistent drug absorption.

Retatrutide is administered as a subcutaneous injection into areas of the body with sufficient fatty tissue. The three primary recommended injection sites are:

• The abdomen — at least 5 cm away from the navel

• The front of the thighs — the outer, upper portion

• The upper outer arms — typically used when a carer or healthcare professional is administering the injection

Rotating injection sites is a critical aspect of safe administration. Repeatedly injecting into the same spot can lead to lipohypertrophy — a localised thickening or hardening of fatty tissue — which can impair drug absorption and reduce the medication's effectiveness. To avoid this, systematically move between different areas and within each area, spacing each injection at least 1–2 cm from the previous site, in line with FIT UK Injection Technique Recommendations.

A practical approach is to divide each injection zone into a grid and work methodically through the sections over successive weeks. Keeping a simple injection diary or using a body diagram can help track rotation. Avoid injecting into:

• Skin that is bruised, tender, scarred, or affected by a rash

• Areas with visible lipohypertrophy or lipoatrophy (sunken skin)

• The waistband area or near bony prominences

If you notice persistent lumps, skin changes, or unusual discomfort at injection sites, report these to your healthcare professional promptly. Proper site rotation not only protects the skin but also ensures consistent drug delivery and optimal therapeutic outcomes.

Side Effects to Be Aware of When Using Retatrutide

The most common side effects are gastrointestinal, including nausea and vomiting; serious effects such as pancreatitis, hypoglycaemia, and injection site reactions should be reported to your clinical team promptly.

As with other GLP-1-based therapies, the most commonly reported side effects of retatrutide in clinical trials are gastrointestinal in nature. These include:

• Nausea

• Vomiting

• Diarrhoea

• Constipation

• Abdominal discomfort or bloating

• Reduced appetite (which may be intentional but can become excessive)

These effects are typically most pronounced during the dose-escalation phase and tend to diminish as the body adjusts to the medication. Eating smaller, lower-fat meals and avoiding rich or spicy foods can help manage nausea. Staying well hydrated is particularly important if vomiting or diarrhoea occurs, as persistent fluid loss can place strain on the kidneys. If you experience severe or prolonged vomiting or diarrhoea, seek medical advice promptly, as temporary interruption of the medication may be necessary.

More serious but less common adverse effects observed across the incretin drug class — and under investigation for retatrutide — include:

• Pancreatitis: Seek urgent medical attention if you experience severe, persistent abdominal pain, particularly if it radiates to the back.

• Gallbladder disease: Significant weight loss associated with GLP-1 therapies may increase the risk of gallstones.

• Hypoglycaemia: Particularly relevant if retatrutide is used alongside insulin or sulphonylureas.

• Injection site reactions: Redness, swelling, or itching at the injection site.

• Increased heart rate: A small increase in resting heart rate has been observed as a class effect with incretin-based therapies. Discuss this with your clinician if you have an existing heart condition.

• Diabetic retinopathy: Rapid improvement in blood glucose control has been associated with worsening of diabetic retinopathy in people with pre-existing eye disease. If you have diabetic retinopathy, ensure your eye health is monitored and report any new or worsening visual symptoms to your clinical team promptly.

• Effects on oral medicines: Because retatrutide slows gastric emptying, it may affect the absorption of some oral medicines, including contraceptives and medicines with a narrow therapeutic index. Discuss the management of any such medicines — including contraception — with your clinician.

Regarding thyroid effects: rodent studies with related GLP-1 receptor agonists have shown C-cell changes, but no causal link to thyroid tumours in humans has been established in UK or EU regulatory assessments. If you have a personal or family history of thyroid cancer, discuss this with your clinician before use; this does not constitute a confirmed contraindication under current UK or EU guidance.

Regarding mood and mental health: a review by the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) found no confirmed causal link between GLP-1 receptor agonists and suicidal ideation or self-harm. Nevertheless, if you notice significant changes in your mood or mental wellbeing, seek support from your GP or clinical team.

Pregnancy and breastfeeding: Retatrutide is not recommended during pregnancy or breastfeeding, as its safety in these situations has not been established. Women of childbearing potential should discuss contraception and pregnancy planning with their clinician before starting treatment.

Reporting side effects: If you experience a suspected side effect, report it to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk or via the Yellow Card app. Reporting helps improve the safety monitoring of medicines for everyone.

Storage, Disposal, and When to Seek Medical Advice

Follow your trial protocol for storage; dispose of used sharps in an approved sharps bin, and seek urgent medical advice for severe abdominal pain, allergic reactions, or signs of anaphylaxis.

Because no approved UK SmPC exists for retatrutide, all storage instructions must be followed as specified in your clinical trial protocol or as directed by your trial team. Do not rely on storage timelines from other injectable medicines, as these may not apply. General principles for injectable biologics include keeping the medicine refrigerated and protected from light and freezing, but your trial documentation will provide the authoritative guidance for your specific product.

If you are uncertain about whether your medication has been stored correctly — for example, if it has been left out for longer than instructed or accidentally frozen — contact your clinical team before using it.

Safe disposal of used needles and devices is a legal and public health responsibility. Used sharps must be placed in an approved sharps bin (yellow-lidded container), which can be obtained from your GP surgery or local pharmacy. Never dispose of needles in household waste or recycling. Full sharps bins should be returned to a designated collection point — your local council or NHS trust can advise on the nearest facility. Further guidance is available from NHS and local council sharps disposal services.

You should contact your GP or clinical team promptly if you experience:

• Severe or persistent nausea, vomiting, or abdominal pain

• Signs of an allergic reaction (swelling of the face, lips, or throat; difficulty breathing; rapid heartbeat)

• Symptoms of low blood sugar (shakiness, sweating, confusion)

• New or worsening visual symptoms

• Significant changes in mood or mental wellbeing

• Signs of dehydration following persistent vomiting or diarrhoea (dizziness, reduced urine output, extreme thirst)

Call 999 or go to your nearest A&E if you develop severe chest pain, difficulty breathing, or signs of anaphylaxis. Always carry information about your medication with you, and inform all healthcare professionals involved in your care that you are participating in a retatrutide clinical trial.

Report any suspected side effects to the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or via the Yellow Card app.

Frequently Asked Questions